Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 88 clinical trials
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual …

  • 246 views
  • 16 Feb, 2022
  • 495 locations
Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer

Capecitabine combined with pyrotinib is the standard protocol for HR+/HER2+ advanced breast cancer after trastuzumab failure, but the incidence of grade 3 hand-foot-syndrome was 16.4%. Therefore, the search for efficient and low toxicity alternatives has become a research hotspot. Our previous basic studies have shown that ER inhibitor fulvestrant and …

  • 0 views
  • 26 Jan, 2021
  • 1 location
Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas

This research is being done to see how safe and effective the use of the study drug Ado-trastuzumab (T) emtansine (DM1), T-DM1, and standard of care chemoradiation are when used together in treating HER2-positive salivary gland cancer. It will also examine the effectiveness of study drug Ado-trastuzumab (T) emtansine (DM1) …

  • 1 views
  • 09 Jan, 2022
  • 2 locations
Testing a New Imaging Agent to Identify Cancer

The purpose of this study is to see whether 89Zr-ss-pertuzumab is safe in people with HER2+ cancer.

  • 0 views
  • 16 May, 2022
  • 1 location
Omission of Radiation in Patients With Her-2 Positive Breast Cancer

The primary objective of this study is to describe the rate of local control in patients with her-2 positive early stage breast cancer with a complete response to chemotherapy and lumpectomy

breast cancer staging
her-2 positive breast cancer
ductal carcinoma
trastuzumab
her-2
  • 148 views
  • 27 Feb, 2022
  • 1 location
Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer (NeoChAI)

This is an exploratory interventional study that initiates chemotherapy with letrozole in patients with estrogen receptor positive/HER2-negative breast cancer preoperably.

adjuvant chemotherapy
docetaxel
cyclophosphamide
letrozole
immunohistochemistry
  • 4 views
  • 02 Mar, 2022
  • 1 location
Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

The main purpose of this study is to evaluate the safety of each study vaccine and to evaluate the effect on the time to disease recurrence (assessed by disease free survival). Participants will be assigned to receive one of two study vaccines (DC1 study vaccine vs. WOKVAC). The study vaccine …

trastuzumab
hemoglobin a1c
her-2 positive breast cancer
her2 positive breast cancer
her-2
  • 268 views
  • 07 Apr, 2022
  • 7 locations
PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast Cancer

This is an open label, randomized, multicenter, international phase II study for premenopausal patients with hormone receptor positive, HER2 negative metastatic or locally advanced breast cancer. Patients will be randomized to receive either palbociclib + exemestane + OFS (Arm 1) or exemestane +OFS (Arm 2). Treatment will be continued until …

  • 0 views
  • 05 Aug, 2021
  • 1 location
Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

The goal of this protocol is to evaluate the safety and efficacy of an alternative systemic combination approach that omits or delays the use of chemotherapy in metastatic disease, while improving efficacy and durability of response. The approach combines two potentially effective and previously studied strategies: androgen receptor blockade and …

systemic chemotherapy
triple negative breast cancer
growth factor
bicalutamide
cancer
  • 0 views
  • 26 Mar, 2022
  • 1 location
Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer. (2019-101826)

This is an open label study of tucatinib in combination with either vinorelbine or gemcitabine and trastuzumab in patients with metastatic HER2+ breast cancer.

  • 0 views
  • 26 Mar, 2022
  • 3 locations